SEOUL, Oct. 17 (Korea Bizwire) — South Korean pharmaceutical companies are intensifying efforts to develop combination drugs — single pills that treat multiple conditions — as patient demand for convenience and cost efficiency rises. Combination drugs contain two or more active ingredients, allowing patients to reduce pill intake and treatment expenses. According to industry sources [...]
SEOUL, Sept. 22 (Korea Bizwire) — A string of hacking incidents at South Korea’s telecommunications and financial companies has prompted pharmaceutical and biotech firms to tighten their defenses, wary that breaches involving sensitive clinical data and intellectual property could trigger irreparable damage. Industry officials said this week that companies are moving quickly to reinforce security policies [...]
SEOUL, July 20 (Korea Bizwire) — South Korean pharmaceutical companies will start selling generic versions of the smoking cessation drug Champix, following the expiration of its patent here, industry sources said Monday. The drug by U.S. pharmaceutical giant Pfizer, also referred to as varenicline tartrate, helps people to stop smoking by relieving cravings for nicotine [...]
SEOUL, April 2 (Korea Bizwire) — Artificial intelligence (AI), expected to change the paradigm of new drug development, is gaining new attention as it has proven to be very effective in the global battle with the coronavirus. As the world suffers from the spread of COVID-19, the need for speed when it comes to discovering [...]
SEOUL, Jan. 13 (Korea Bizwire) — Major South Korean pharmaceutical companies are ramping up the phase-three clinical trials of their key products in China as they seek to tap deeper into the world’s second largest bio market. Samsung Bioepis Co. said it is awaiting approval from Chinese health authorities for the final stage of clinical [...]
SEOUL, Sept. 1 (Korea Bizwire) — Bio shares on the Korean stock market tumbled this year as investor confidence was hurt by a series of scandals involving major drugmakers, data showed Saturday. The combined market capitalization of 43 pharmaceutical and bio companies listed on the main bourse, the KOSPI, stood at 81.3 trillion won (US$67.2 [...]
SEOUL, May 30 (Korea Bizwire) — The market value of pharmaceuticals traded on South Korea’s minor bourse has plunged over the past two months due to a gene therapy drug scandal, data showed Thursday. The pharmaceutical industry index of the KOSDAQ market closed at 8,558.65 Wednesday, down 11.8 percent from two months earlier when the [...]
SEOUL, Jan. 22 (Korea Bizwire) — Exports of drug-manufacturing technologies by South Korean pharmaceutical and bio companies reached nearly 5.3 trillion won (US$4.7 billion) in 2018 thanks to their efforts to tap into overseas markets, government data showed Tuesday. According to the data by the Ministry of Health and Welfare, industry player Yuhan Corp. and [...]
SEOUL, Aug. 16 (Korea Bizwire) — Major South Korean pharmaceutical companies expanded their spending on research and development (R&D) during the first half this year, with Hanmi Pharmaceutical Co. allocating the most, industry data showed Wednesday. According to their semi-annual business reports, 10 out of the 15 drug companies spent more on R&D during the [...]
SEOUL, Jan. 21 (Korea Bizwire) – South Korea’s major pharmaceutical companies are poised to sharply expand their spending on research and development (R&D) in 2016, taking a page from Hanmi Pharmaceutical Co.’s aggressive investment that has led to a series of mega-hit licensing deals, industry sources said Thursday. Of the country’s top 10 drug companies [...]